Your browser doesn't support javascript.
loading
Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 Infection With Extended-Duration Nirmatrelvir-Ritonavir Among Outpatients With Hematologic Cancer.
Liu, Catherine; Yoke, Leah H; Bhattacharyya, Pooja; Cassaday, Ryan D; Cheng, Guang-Shing; Escobar, Zahra Kassamali; Ghiuzeli, Cristina; McCulloch, Denise J; Pergam, Steven A; Roychoudhury, Pavitra; Tverdek, Frank; Schiffer, Joshua T; Ford, Emily S.
Afiliação
  • Liu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Yoke LH; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Bhattacharyya P; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Cassaday RD; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Cheng GS; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Escobar ZK; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Ghiuzeli C; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • McCulloch DJ; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Pergam SA; Division of Hematology, University of Washington, Seattle, Washington, USA.
  • Roychoudhury P; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Tverdek F; Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, Washington, USA.
  • Schiffer JT; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Ford ES; School of Pharmacy, University of Washington, Seattle, Washington, USA.
Open Forum Infect Dis ; 10(6): ofad306, 2023 Jun.
Article em En | MEDLINE | ID: mdl-37383248
Persistent symptomatic coronavirus disease 2019 (COVID-19) is a distinct clinical entity among patients with hematologic cancer and/or profound immunosuppression. The optimal medical management is unknown. We describe 2 patients who had symptomatic COVID-19 for almost 6 months and were successfully treated in the ambulatory setting with extended courses of nirmatrelvir-ritonavir.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article